secwatch.observer — SEC 8-K summary
======================================

Issuer:     Reliance Global Group, Inc. (EZRA)
CIK:        0001812727
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001493152-26-021123
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reliance Global Group invests $2M in Innervate Radiopharmaceuticals via LifeSci Global biotech arm
--------------------------------------------------------------------------------

- LifeSci Global (51% owned by Reliance) agrees to acquire 421,053 Innervate units at $4.75/unit for $2M total; $500K funded at closing.
- Innervate develops 18F-mFBG PET imaging for neuroblastoma; initial market ~$250M with potential $1B+ expansion in cardiovascular/neurodegenerative.
- Reliance subsidiary EIG issued a $2M promissory note at 7% interest to LifeSci Global to fund the investment; matures April 2031.
- CEO Beyman and director Korman have indirect equity in LifeSci Global and recused from board approval; Korman removed from all board committees.
- Company highlights potential Rare Pediatric Disease Priority Review Voucher if Innervate's product is approved, which could be monetized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812727/000149315226021123/0001493152-26-021123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812727/000149315226021123/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-021123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer